---
title: "Citi Raises CSPC PHARMA  TP to HKD15 as 3Q Results Beat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306056531.md"
description: "Citi raised its target price for CSPC PHARMA to HKD15 from HKD14.6, maintaining a Buy rating after the company's Q3 results beat expectations. The upgrade was driven by licensing income and core business recovery. Citi increased its 2026 revenue and net profit forecasts by 2% and 3% respectively, citing improved cost efficiency and normalized milestone income."
datetime: "2026-11-19T03:43:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306056531.md)
  - [en](https://longbridge.com/en/news/306056531.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306056531.md)
generator: "portal-rs"
---

# Citi Raises CSPC PHARMA  TP to HKD15 as 3Q Results Beat

Citi published a report stating that CSPC PHARMA (01093.HK) +0.225 (+2.818%) Short selling $210.70M; Ratio 36.668% 's 3Q results beat expectations, benefiting from licensing income and a recovery in its core business. The broker raised the TP from HKD14.6 to HKD15 and maintained its Buy rating.

The broker said the recovery in core drug sales, improved cost efficiency, and the increasing normalization of milestone income from business expansion are favorable to earnings visibility. Revenue from the central nervous system (CNS) business rose 29.1% YoY in the first nine months, accounting for about 48% of finished drug sales excluding licensing contributions. Management expects more than 10 new products and indications to be launched next year, supporting overall positive growth.

The broker raised its 2026 revenue forecast by 2% and increased its 2026 net profit forecast by 3% on assumptions of higher margins, while making slight adjustments to its 2027 and 2028 forecasts. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-18 16:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Alibaba Q2 revenue rises on AI Cloud and Compute Services strength](https://longbridge.com/en/news/306100634.md)
- [CSPC Pharmaceutical Starts Phase II Trial of SYH2072 for Hypertension in China](https://longbridge.com/en/news/304096545.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**